Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Key Sessions

Sander Slootweg

Keynote Chat: Navigating VC Investment, Focus, & Trends

Forbion Capital Partners

Mar 24
Show Filter
09:00 - 10:00 60 mins
Registration and Networking Breakfast
10:00 - 10:15 15 mins
Opening Remarks

Wendy Nelson, CEO, LeadingBiotech

Johannes Sarx, Managing Director LISAvienna

10:15 - 11:00 45 mins
Shifting the Paradigm; Encouraging a Culture of Entrepreneurship in Europe’s Biotech Industry

What kind of people are needed to make a successful, sustainable biotech? What changes are needed to encourage, recruit and retain a robust life science community throughout Europe?

  • Annalisa Jenkins - CEO, PlaqueTec Ltd
  • Don deBethizy - Chairman, Albumedix
  • Nathalie Rowell - CEO, Virdis Group
  • Robert Ladner - CEO, CV6 Therapeutics
11:30 - 12:00 30 mins
Networking Break
12:00 - 12:30 30 mins
Public Markets: What are the Implications of Listing in Europe vs the US

Look at the difference between going public in Europe vs the US for European-based biotech companies, current trends, and the implications for listing

  • Adam Kostyál - SVP - Head of Listings EMEA, Nasdaq
12:30 - 13:00 30 mins
Avoiding the Pitfalls in Pharma Partnerships & Deal Making

What are the elements of a successful partnership, and what lessons can be learned to avoid often overlooked mis-steps?

  • Contributor Tim Luker - Senior Director, Emerging Technology & Innovation, Corporate Business Development, Eli Lilly & Company
  • Contributor John Gustofson - Managing Director, AbbVie Ventures
  • Contributor Nathalie ter Wengel - European Head Worldwide Business Development, Pfizer
13:00 - 14:00 60 mins
Networking Lunch
14:00 - 14:40 40 mins
Creating Long Term Value and Innovation in European Life Sciences

How are stakeholders acting towards creating long term value in the life science community in Europe? How must biotech builders think about their path forward, from compelling science to commercial strategy? 

  • Soren Moller - Managing Partner, Novo Seeds
  • Thomas de Vlaam - CEO, Amylon Therapeutics
  • Moderator Vanessa King - President and CEO, Virion Biotherapeutics
14:40 - 15:10 30 mins
Building a Biotech: Transforming Your Breakthrough Science into a Commercially Viable Asset

What are some of the valuable growth strategies and survival techniques in the early stages of biotech development? Hear other biotech perspectives from peers in various stages of growth and development.

  • contributor Roel Bulthuis - Managing Director, INKEF Capital
  • contributor Pierre Belichard - CEO, Enterome
15:10 - 15:40 30 mins
Investor/Founder Origin Story

Gain candid insight via a remarkable story of Merck spin-off Prexton Therapeutics, including a fascinating exit with the 2018 sale of the company to Lundbeck.

  • Jasper Bos - Managing Director and Senior Vice President, M Ventures
  • Francois Conquet - Founder & CEO, Prexton Therapeutics
15:40 - 16:10 30 mins
Networking Break
16:10 - 16:40 30 mins
Oncology Pipeline: The Path to Drug Development

Asses the latest developments in Oncology from Cell & Gene Therapy, technology enabling Precision Medicine to the latest in CarT & Immunotherapy. 

  • Moderator Tim Herpin - Chief Business Officer, Caribou Biosciences
  • Jane Dancer - CBO, F-star Biotechnology Ltd.
16:40 - 17:10 30 mins
Keynote Address
17:10 - 17:40 30 mins
The Future of European Biotech in a Global Setting

What are the key success factors to compete in a global market? Take a closer look at Europe in the context of the “big picture”  

  • Thomas Lonngren - Former Executive Director, EMA
  • Kevin Lee - CEO, Bicycle Therapeutics
  • John Haurum - Fmr. CEO, F-Star
17:40 - 17:55 15 mins
Closing Remarks
17:55 - 18:55 60 mins
Cocktail Reception & Networking